UK watchdog threatens probe of Vivisol's Air Liquide home-oxygen deal
What's the deal? The UK Competition and Markets Authority said it could open an in-depth investigation into VivisolDealroom has a profile for this one. Try Dealroom →'s acquisition of Air Liquide Healthcare's home-oxygen business, unless the companies ease competition concerns. The deal value is undisclosed.
Who's involved? Dolby Medical Home Respiratory Care, trading as Vivisol, has agreed to buy the Air Liquide Healthcare assets used to supply home-oxygen services to UK National Health Service patients. Vivisol is a subsidiary of Italy-listed Sol.
The concern: The CMA said Thursday that an initial investigation found the deal might result in "a substantial lessening of competition" in the UK. Both Vivisol and Air Liquide currently provide home-oxygen services to NHS patients.
Why now? The companies have until November 26 to offer remedies. If they don't — or if the CMA deems them insufficient — the watchdog will refer the merger for an in-depth Phase 2 investigation.
What could go wrong? A Phase 2 referral would extend scrutiny and could delay or block the deal. With both buyer and target serving NHS patients, overlap in a state-funded market raises the bar for approval.
The signal: The case shows how consolidation among home-healthcare providers draws tight regulatory review when the end customer is a public health system. For acquirers in the sector, clearing competition hurdles is now central to the deal.
Read more: marketscreener.com
Image credit: Generated with Gemini